cyrilzakka/clinical-trials huggingface dataset:
Relationship Between Serum Vitamin D Levels and Postherpetic Neuralgia.

1. The correlations of serum vitamin D level, serum calcium level and osteoporosis degree with disease severity, treatment response, incidence of Post-Herpes zoster(PHN) and disease prognosis in Herpes zoster(HZ) patients were studied.
2. To investigate the role of inflammation-related factors and immune-related factors in the occurrence and development of HZ mediated by low vitamin D level.

Herpes zoster is a neuropathic disease which induce by the varicella-herpes virus reactivation.and postherpetic neuralgia (PHN) is the most common complication. Currently,the mechanism of herpes zoster still unclearly even though there had much study about it .Vitamin D is an essential vitamin for human body, which has the function of maintaining calcium and phosphorus homeostasis and immune regulation. Vitamin D is a natural antiviral substance, and vitamin D deficiency can affect the body's antiviral ability, thereby promoting varicella-zoster virus(VZV) reactivation, and may promote the development of PHN through continuous neuroinflammation. Therefore, vitamin D level may be related to the occurrence and progression of HZ. this study intends to use an observational cohort study design to investigate the correlation of serum vitamin D level and osteoporosis degree with the severity of the herpes zoster disease, Although we plan to further explore the role of inflammatory state in this process.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years.
* The patient was diagnosed with herpetic neuralgia and the course of disease was ≤3 months.
* Can cooperate with the completion of inquiry and scale evaluation.

Exclusion Criteria:

* Severe spinal disease (fracture, malignancy, acute or chronic infection) confirmed by previous spinal surgery or imaging.
* Previous history of head trauma.
* Have autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, leucothrombocytopenia).
* Suffering from mental disorders, intellectual disability, epilepsy and other diseases.
* A history of substance abuse, drug abuse or alcohol abuse.
* Pregnant or breastfeeding women.
* And recent participation in other clinical studies.
Polyethylene Glycol to Improve Sensation Following Digital Nerve Laceration

PEG is a fusogen, a type of chemical that aids in mediating cell fusion. PEG helps nerve cells recover neuronal continuity by removing plasmalemmal-bound water which opens the axonal ends on both sides of the injury. Opening axonal ends permits the nerve ends to reconnect and begin regeneration. PEG has been tested on animal models extensively and in earthworm models has been shown to induce fusion rates in 80-100% of neuronal cells. In crushed or severed mammalian sciatic nerves PEG has enhanced neuronal continuity to baseline functioning levels.

Human applications for PEG have been tested by Bamba and colleagues in a case series with encouraging results. No studies, to our knowledge, have prospectively examined the use of PEG in peripheral nerve injuries. We propose a placebo controlled, double-blinded randomized controlled trial to test the hypothesis that local PEG administration can enhance sensory nerve regeneration following digital nerve transection compared to surgery alone.


Eligibility Criteria:
Inclusion Criteria:

* (1) surgery within twenty-four hours of injury (2) surgery completed in the minor procedures unit of the Halifax Infirmary.

Exclusion Criteria:

* (1) patients with cognitive impairment
S3 Root Pulsed Radiofrequency Added to Superior Hypogstric Plexus Block

The investigators hypothesis that adding pulsed radiofrequency neuromodulation at S3 nerve root to superior hypogastric plexus chemical neurolysis improves analgesia in patients with chronic pelvic cancer pain.


Eligibility Criteria:
Inclusion Criteria:

* pelvic cancer patients
* with pelvic pain not responding to oral analgesic medications
* side effects of oral analgesic medications

Exclusion Criteria:

* patients with metastatic cancer disease
* patients with significantly impaired organ functions
* patients with bleeding diathesis
* patients with mental disabilities
E-support for Healthcare Processes - WEIGHT LOSS

The purpose of the study is to establish and clinically evaluate a new approach to treating obesity by using information and communication technologies (ICT). A mobile environment and organizational interventions to improve the process of an integrated treatment of people with obesity will be identified, developed, introduced and clinically evaluated.

A mobile environment to improve the process of an integrated treatment of obese people will be identified, developed, introduced and clinically evaluated. The study will include 150 patients aged between 25 to 65 for men and 25 to 70 for women, diagnosed with obesity (BMI≥30 or BMI\>27,5 and 20% risk or more for developing a cardiovascular diseases). One group of patients will visit conventional live workshops for weight loss and the other group will use ICT. At the initial examination by the doctor all survey participants will have measured blood pressure, body mass, waist circumference, percentage of body fat, percentage of skeletal muscle, resting metabolic rate, estimated risk of developing cardiovascular disease and will be directed to laboratory examination (blood lipids and cholesterol, blood sugar). Both groups will go through 16 workshops for weight loss. Each week they will monitor their body mass, waist circumference, physical activity (type, duration, intensity) and food intake (type, quantity). After six months all survey participants will be examined again. We will compare effectiveness of ICT weight loss group with conventional weight loss group.

Eligibility Criteria:
Inclusion Criteria:

* BMI≥30 or BMI\>27,5 and 20% or more risk for developing a cardiovascular diseases
* Age between 25 - 65 years for men and 25 - 70 years for women
* Own a mobile phone
* Internet
* Know how to use a computer
* Know how to use an e-mail
* Signed voluntary consent to participate in the survey

Exclusion Criteria:

* People with movement disorders
* Age\<18 years or age\>70 years for women and 65 years for men
* Pregnancy, breast feeding, intention of getting pregnant during the study, period after childbirth (9 months)
* Does not own or know how to handle a mobile phone
* No internet access
* Known hospitalization for severe psychiatric disorders (schizophrenia, psychosis)
* Known history of eating disorders (anorexia, bulimia nervosa and others)
* Cancer incidence in the last 5 years
* Heart problems, chest pain, nausea, dizziness
* Chronic inflammatory diseases
* Other unregulated chronic diseases
Oral Health Literacy Tailored Communication

The purpose of this study to investigate attitude, oral health literacy and psychological factors in order to evaluate if these factors are important for oral health in adults.

The hypotheses are:

* Multiple interactive demographic, and social and psychological factors contribute to the level of attitude and oral health literacy.
* There is an association between the level of oral health literacy and oral health status
* A structured intervention based on oral health literacy can change the attitude and improve the oral health status.
* Background knowledge has influence on attitude and oral health literacy
* Individuals with positive attitude towards dental health and dentist are attentive towards their oral health.

This study will be conducted in two stages. The first stage includes a baseline cross-sectional investigation. Oral health literacy level will be assessed by conducting a structured interview. Background variables, attitude, socioeconomic factors and psychological factors shall be assessed using self-administered questionnaires. A clinical examination will be conducted including general health information and extended oral health examination. The oral health examination performed includes record of oral hygiene status such as dental caries and periodontal status. An assessment of oral bacteria will also be performed.

The second stage will be carried out approximately 6 months after starting with the baseline investigation. At that time a modified version of the questionnaires will be used followed by a shorter clinical examination. The modified questionnaires at the second data collection exclude some background variables. The clinical examination carried out during this time will be on dental plaque and bleeding index and the level of oral bacteria.

Eligibility Criteria:
Inclusion Criteria:

* Participants \> 20 years of age.
* Participants who master the Norwegian language.
* Participants who are registered at the university dental clinic (IKO).

Exclusion Criteria:

* People who do not master the Norwegian language.
* Strongly visually impaired people that have difficulty in reading.
* People with a history of heart-attack in the past 6 months.
* Immune- compromised people and organ- transplanted people.
* People with other conditions that might lead to more disadvantages than advantages by participating
Biomarkers Associated With Postoperative Cognitive Dysfunction

Loss of cognitive function after major surgery is a significant risk in older people. It can occur acutely in the days after surgery as delirium or in months to years later as a persistent reduction in brain function termed neurocognitive decline. Together these conditions are called post operative cognitive dysfunction (POCD). They can be acutely distressing for patients and are associated with other problems after surgery.

The causes of post operative cognitive dysfunction are poorly understood. Studies have been limited by a lack of biomarkers to predict which patients are at high risk of developing POCD. Research suggests silent strokes occurring during surgery and different sensitivities to anaesthetic medicines are associated with POCD.

The project consists of a feasibility study to investigate markers that might predict people over 65 years old getting POCD. The first biomarker is a non-invasive monitor of anaesthetics effects on brain function called electroencephalography (EEG): The investigators will identify which EEG patterns predict delirium within five days surgery. The second set of biomarkers are two blood tests of proteins that increase after strokes: these are neurofilament light chains and tau proteins. The investigators will establish if these can be used to predict having POCD up to one year after surgery and long term cognitive impairment up to 5 years after surgery.


Eligibility Criteria:
Inclusion Criteria:

* Greater than or equal to 65 years of age
* Having elective non-cardiac surgery under general anaesthesia
* Anticipated to have at least 48 hours of inpatient admission
* Able \& willing to give informed consent

Exclusion Criteria:

* Unable to participate in neurocognitive assessments
* Presence of delirium prior to surgery
* Contraindication to use of EEG electrodes (e.g. known allergy to a component of the electrodes)
* Known history of severe traumatic brain injury
* Learning disability specifically with a known structural brain lesion
* Known history of dementia
* Participants undergoing operations on the carotid artery
Treatment of Androgenetic Alopecia in Females, 12 Beam

The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 12 beam model for androgenetic alopecia in females when treatment is applied as directed.

This is a randomized double-blind, sham controlled clinical study, evaluating changes in terminal hair count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).

The trial with 63 female subjects, who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Ludwig I-4, II-1, II-2, or frontal, have active hair loss within the last 12 months.

Subjects will use the device on three non-concurring days a week as directed per device for 26 weeks duration.

Initial efficacy endpoint for each subject will be assessed at visit 4 (week 16).

Safety analysis will be assessed based on the reports of adverse events during study.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of androgenetic alopecia
* Fitzpatrick Skin types I-IV
* Ludwig I-4, II-1, II-2, or frontal
* Active hair loss within last 12 months

Exclusion Criteria:

* Photosensitivity to laser light
* Malignancy in the target area
* Pregnancy
* Lactating females
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer

This study aims to probe the effect of SBRT as a treatment oligometastases of prostate cancer, regardless of basal treatment received, and I know the response, biochemical control, the progression-free survival as well as their impact on quality of life.

Primary Objective: Local and symptomatic oligometastases Control of prostate cancer treated by SBRT.

Secondary Objectives: Analyzing biochemical progression rates, progression-free survival, chemotherapy-free survival and overall survival. Analyze toxicities and quality of life of patients before and after treatment


Eligibility Criteria:
Inclusion Criteria:

* Patients with histologically confirmed prostate cancer, who are currently being oligometastases / oligorrecurrencia after primary treatment for their disease.
* Aged ≥ 18 years
* Time to biochemical recurrence more than 1 year
* PSA doubling time\> 3 months
* Less than 5 bone metastases location (including spinal) or lymph node.
* Without other metastases or recurrences by Choline PET or / and NMR Diffusion Length.
* Signed and dated written informed consent form.

Exclusion Criteria:

* Patients currently treatment with abiraterone, enzalutamide, chemotherapy, immunotherapy or radioisotopes.
* Patients unwilling or unable to comply with protocol requirements and scheduled visits.
The Fate Of Calf Perforators After Endovenous Laser Ablation Of Saphenous Veins

The aim of this study is to evaluate the morphologic and hemodynamic changes in the calf perforators after endovenous laser ablation of saphenous veins.


Eligibility Criteria:
Inclusion Criteria:

* Symptomatic patients who undergo EVLA procedure for saphenous vein insufficiency

Exclusion Criteria:

* Patients with a history of deep venous thrombosis (DVT)
* Previous varicose vein surgery or injection sclerotherapy
* Patients without superficial venous incompetency
Greater Occipital Nerve Block Versus Pulse Radiofrequency in Migraine

The aim of the study is to evaluate the clinical efficacy of the repeated greater occipital nerve(GON) blokcs with GON pulse radiofreaquency (PRF)

The nerve blocks will be performed at the Cervical-2 (C2) level with ultrasound guidance.Also , the PRF will be done as above proximally.

Eligibility Criteria:
Inclusion Criteria:

* ICHD- migraine with minimum 4 attacks
* no benefit with proflactic therapies

Exclusion Criteria:

* primary headhache other than migraine according to ICHD
* the change of medical teatment of migrane in last 1 month.
The Effect of Reading Fairy Tales and Coloring on Children's Fear Level in Children Who Are Administered Inhaler Medication With a Mask.

This thesis study was conducted as an unblinded, randomized controlled experiment to examine the effects of reading and coloring fairy tales, which can be used during inhaler medication administration with a mask, on children's fear level and parental health care satisfaction.

Data were collected at Edirne Sultan 1. Murat State Hospital Pediatrics Clinic between September 2023 and January 2024. Children aged 3-6 were included in the study. In the research, the sample was divided into three groups. 99 children participated in the study, 33 children in each group. Using the randomization program, it was determined which sample group the children would be included in.

In the study, reading fairy tales and coloring were used as distraction methods for the experimental group. Inhaler medication was administered via mask to the control group without any application. The implementation period of the research lasted an average of four months. Necessary ethical permissions were obtained before the research. In the study, the Child Fear Scale was used to measure the level of fear, the PedsQL Health Care Satisfaction Scale was used to measure parental satisfaction, and the Children's Emotional Indicators Scale was used to measure emotional indicators. Explanatory information about the application was given to the children and their parents by the researcher, and they were voluntarily informed and signed a consent form. Research data were collected by the researcher by meeting children and parents face to face.

Eligibility Criteria:
Inclusion Criteria:

1. Parent and child volunteering to participate in the study,
2. The child is between the ages of 3-6,
3. Being admitted due to respiratory system disease,
4. Inhaler treatment with a mask will be applied.

Exclusion Criteria:

1. Parent and child not voluntarily participating in the study,
2. The child has any genetic, congenital, chronic or metabolic disease,
3. The child has vision, hearing and speech problems,
4. The child's vital signs are unstable (no fever, tachypnea, etc.) and the need for any emergency intervention.
ALDH1A1 Expression in Invasive Mammary Carcinoma

ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs.

Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .

Breast cancer is one of the most common cancers among women. it is a heterogenous disease. several factors affect the prognosis of breast cancer. CSCs markers are one of the emerging prognostic biomarkers.

ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs.

Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .

Eligibility Criteria:
Inclusion Criteria:

* Patients with invasive mammary carcinoma carcinoma and underwent surgery

Exclusion Criteria:

* Cases received pre-operative chemotherapy or radiotherapy.
* Cases with insufficient clinical data.
Efficacy of Serratus Posterior Intercostal Plane Block for Analgesia and Inflammatory Marker in Breast Surgery

To study the efficiacy of serratus posterior superior block in controlling perioperative breast cancer surgery pain and its effect on inflamatory markers.

Back ground The presence of pain during the initial course of treatment in women with early-stage breast cancer was associated with significantly higher levels of c-reactive protein(CRP) ,interleukin-7(IL-7)and interleukin-13(IL-13) There is evidence of effectiveness of regional block in controlling inflamatory markers Serratus posterior superior intercostal plane block (SPSIPB) is a novel Regional technique that provides analgesia in the hemithorax, shoulder, and back of the neck which proved its efficacy in controlling pain after Video assisted thoracoscopic surgery there are little epidemiological data on (SPSIPB)usage in masectomy and lumpectomy procedures and its effect on inflamatory markers

Methodology:

* Type of the Study: Randomized prospective comparative controlled double-blinded study

  * Study Setting: Ain Shams University Hospitals
  * Study Period: One year after approval of the protocol.
  * Place :Ain shams university hospitals
  * Study Population: Adult patients who will undergo breast cancer surgey.

Eligibility Criteria:
Inclusion Criteria:

* Adults undergoing unilateral breast surgery under general anesthesia
* Age 21 to 60 years with body mass index (BMI)=18 to 25 kg/m2
* American Society of Anesthesiologists (ASA) grade I-III.

Exclusion Criteria:

* Patients with Long-time use of analgesic drugs
* Past history of chest surgery,
* Allergy to local anesthetics,
* Systemic infection,
* Cognitive and language disorders precluding participation,
* Patients with coagulopathy,anticoagulant users
* hemodynamic unstable patients
* Patients with neurology, spinal, psychiatry diseases
* infection at block site
* patients refused to participate in the study .
Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension

The primary objective is to compare the efficacy of irbesartan/hydrochlorothiazide 300/25mg against valsartan/hydrochlorothiazide 160/25mg in reducing mean systolic blood pressure (SBP) as measured by home blood pressure monitoring (HBPM) after 24 weeks compared with baseline.

The secondary objectives are:

* To compare the percentage of patients with normal blood pressure as measured by HBPM and at the doctor's office at weeks 16 and 24
* To compare the differences in mean Diastolic Blood Pressure (DBP), mean morning and evening SBP and DBP evaluated by HBPM at weeks 16 and 24
* To compare the difference in mean SBP evaluated by HBPM at week 16
* To compare the differences in mean SBP and DBP evaluated at the doctor's office at weeks 16 and 24
* To determine the incidence and severity of adverse events


Eligibility Criteria:
Inclusion Criteria:

* Established essential hypertension, untreated or treated but uncontrolled with treatment:

  * Office SBP ≥ 160 mmHg for untreated patients
  * Office SBP ≥ 140 mmHg for patients already treated with an antihypertensive drug.
* Previous antihypertensive therapy must have been implemented for a minimum of 4 weeks and must be either monotherapy or one of the following permitted combination drugs:

  * ACE inhibitor / calcium channel blocker
  * Beta blocker / calcium channel blocker
  * Beta blocker / low dose diuretic
  * ACE inhibitor / low dose diuretic

Exclusion Criteria:

* SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg evaluated at doctor's office at Visit 1
* Known or suspected causes of secondary hypertension
* Patient with bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, a renal transplant or only has one functioning kidney
* Type 1 diabetes mellitus
* Significant cardiovascular, neurological, endocrine, renal, metabolic, or gastrointestinal disease, a malignancy or any other diseases considered by the Investigator to make participation in the study not in the best interest of the subject
* Known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough related to the administration of an angiotensin II receptor antagonist or any combination of the drugs used
* Known contraindications to any of the study drugs
* Concomitant use of any other antihypertensive treatment
* Use of any of the investigational products for this study within the 3 months prior to the study
* Inability to obtain a valid HBPM recording i.e., obesity, arm circumference \> 32 cm or arrhythmia
* Administration of any other investigational drug in the last 30 days before enrolment and during the course of the study
* Pregnant or breast-feeding women
* Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.